Antibody-mediated protection against MERS-CoV in the murine model.
Identifieur interne : 000508 ( PubMed/Curation ); précédent : 000507; suivant : 000509Antibody-mediated protection against MERS-CoV in the murine model.
Auteurs : R R C. New [Royaume-Uni] ; B D Moore [Royaume-Uni] ; W. Butcher [Royaume-Uni] ; R. Mahood [Royaume-Uni] ; M S Lever [Royaume-Uni] ; S. Smither [Royaume-Uni] ; L. O'Brien [Royaume-Uni] ; S A Weller [Royaume-Uni] ; M. Bayliss [Royaume-Uni] ; L C D. Gibson [Royaume-Uni] ; C. Macleod [Royaume-Uni] ; M. Bogus [Royaume-Uni] ; R. Harvey [Royaume-Uni] ; N. Almond [Royaume-Uni] ; E D Williamson [Royaume-Uni]Source :
- Vaccine [ 1873-2518 ] ; 2019.
Abstract
Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.
DOI: 10.1016/j.vaccine.2019.05.074
PubMed: 31178378
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000508
Links to Exploration step
pubmed:31178378Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibody-mediated protection against MERS-CoV in the murine model.</title><author><name sortKey="New, R R C" sort="New, R R C" uniqKey="New R" first="R R C" last="New">R R C. New</name><affiliation wicri:level="1"><nlm:affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London</wicri:regionArea></affiliation></author><author><name sortKey="Moore, B D" sort="Moore, B D" uniqKey="Moore B" first="B D" last="Moore">B D Moore</name><affiliation wicri:level="1"><nlm:affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Pure & Applied Chemistry, University of Strathclyde, Glasgow</wicri:regionArea></affiliation></author><author><name sortKey="Butcher, W" sort="Butcher, W" uniqKey="Butcher W" first="W" last="Butcher">W. Butcher</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Mahood, R" sort="Mahood, R" uniqKey="Mahood R" first="R" last="Mahood">R. Mahood</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Lever, M S" sort="Lever, M S" uniqKey="Lever M" first="M S" last="Lever">M S Lever</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Smither, S" sort="Smither, S" uniqKey="Smither S" first="S" last="Smither">S. Smither</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="O Brien, L" sort="O Brien, L" uniqKey="O Brien L" first="L" last="O'Brien">L. O'Brien</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Weller, S A" sort="Weller, S A" uniqKey="Weller S" first="S A" last="Weller">S A Weller</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Bayliss, M" sort="Bayliss, M" uniqKey="Bayliss M" first="M" last="Bayliss">M. Bayliss</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Gibson, L C D" sort="Gibson, L C D" uniqKey="Gibson L" first="L C D" last="Gibson">L C D. Gibson</name><affiliation wicri:level="1"><nlm:affiliation>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow</wicri:regionArea></affiliation></author><author><name sortKey="Macleod, C" sort="Macleod, C" uniqKey="Macleod C" first="C" last="Macleod">C. Macleod</name><affiliation wicri:level="1"><nlm:affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Pure & Applied Chemistry, University of Strathclyde, Glasgow</wicri:regionArea></affiliation></author><author><name sortKey="Bogus, M" sort="Bogus, M" uniqKey="Bogus M" first="M" last="Bogus">M. Bogus</name><affiliation wicri:level="1"><nlm:affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London</wicri:regionArea></affiliation></author><author><name sortKey="Harvey, R" sort="Harvey, R" uniqKey="Harvey R" first="R" last="Harvey">R. Harvey</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute for Biological Standards and Control, Potters Bar</wicri:regionArea></affiliation></author><author><name sortKey="Almond, N" sort="Almond, N" uniqKey="Almond N" first="N" last="Almond">N. Almond</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute for Biological Standards and Control, Potters Bar</wicri:regionArea></affiliation></author><author><name sortKey="Williamson, E D" sort="Williamson, E D" uniqKey="Williamson E" first="E D" last="Williamson">E D Williamson</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK. Electronic address: dewilliamson@dstl.gov.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31178378</idno><idno type="pmid">31178378</idno><idno type="doi">10.1016/j.vaccine.2019.05.074</idno><idno type="wicri:Area/PubMed/Corpus">000508</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000508</idno><idno type="wicri:Area/PubMed/Curation">000508</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000508</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antibody-mediated protection against MERS-CoV in the murine model.</title><author><name sortKey="New, R R C" sort="New, R R C" uniqKey="New R" first="R R C" last="New">R R C. New</name><affiliation wicri:level="1"><nlm:affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London</wicri:regionArea></affiliation></author><author><name sortKey="Moore, B D" sort="Moore, B D" uniqKey="Moore B" first="B D" last="Moore">B D Moore</name><affiliation wicri:level="1"><nlm:affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Pure & Applied Chemistry, University of Strathclyde, Glasgow</wicri:regionArea></affiliation></author><author><name sortKey="Butcher, W" sort="Butcher, W" uniqKey="Butcher W" first="W" last="Butcher">W. Butcher</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Mahood, R" sort="Mahood, R" uniqKey="Mahood R" first="R" last="Mahood">R. Mahood</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Lever, M S" sort="Lever, M S" uniqKey="Lever M" first="M S" last="Lever">M S Lever</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Smither, S" sort="Smither, S" uniqKey="Smither S" first="S" last="Smither">S. Smither</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="O Brien, L" sort="O Brien, L" uniqKey="O Brien L" first="L" last="O'Brien">L. O'Brien</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Weller, S A" sort="Weller, S A" uniqKey="Weller S" first="S A" last="Weller">S A Weller</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Bayliss, M" sort="Bayliss, M" uniqKey="Bayliss M" first="M" last="Bayliss">M. Bayliss</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author><author><name sortKey="Gibson, L C D" sort="Gibson, L C D" uniqKey="Gibson L" first="L C D" last="Gibson">L C D. Gibson</name><affiliation wicri:level="1"><nlm:affiliation>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow</wicri:regionArea></affiliation></author><author><name sortKey="Macleod, C" sort="Macleod, C" uniqKey="Macleod C" first="C" last="Macleod">C. Macleod</name><affiliation wicri:level="1"><nlm:affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Pure & Applied Chemistry, University of Strathclyde, Glasgow</wicri:regionArea></affiliation></author><author><name sortKey="Bogus, M" sort="Bogus, M" uniqKey="Bogus M" first="M" last="Bogus">M. Bogus</name><affiliation wicri:level="1"><nlm:affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London</wicri:regionArea></affiliation></author><author><name sortKey="Harvey, R" sort="Harvey, R" uniqKey="Harvey R" first="R" last="Harvey">R. Harvey</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute for Biological Standards and Control, Potters Bar</wicri:regionArea></affiliation></author><author><name sortKey="Almond, N" sort="Almond, N" uniqKey="Almond N" first="N" last="Almond">N. Almond</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute for Biological Standards and Control, Potters Bar</wicri:regionArea></affiliation></author><author><name sortKey="Williamson, E D" sort="Williamson, E D" uniqKey="Williamson E" first="E D" last="Williamson">E D Williamson</name><affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK. Electronic address: dewilliamson@dstl.gov.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">31178378</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>30</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Antibody-mediated protection against MERS-CoV in the murine model.</ArticleTitle><Pagination><MedlinePgn>4094-4102</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(19)30711-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2019.05.074</ELocationID><Abstract><AbstractText>Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.</AbstractText><CopyrightInformation>Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>New</LastName><ForeName>R R C</ForeName><Initials>RRC</Initials><AffiliationInfo><Affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>B D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butcher</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahood</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lever</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smither</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayliss</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>L C D</ForeName><Initials>LCD</Initials><AffiliationInfo><Affiliation>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macleod</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogus</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almond</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>E D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK. Electronic address: dewilliamson@dstl.gov.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">MERS</Keyword><Keyword MajorTopicYN="N">Mucosal immunity</Keyword><Keyword MajorTopicYN="N">Neutralising antibody</Keyword><Keyword MajorTopicYN="N">Novel vaccine formulation</Keyword><Keyword MajorTopicYN="N">Respiratory infection</Keyword><Keyword MajorTopicYN="N">Systemic immunity</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31178378</ArticleId><ArticleId IdType="pii">S0264-410X(19)30711-X</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2019.05.074</ArticleId><ArticleId IdType="pmc">PMC7115393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Apr;20(4):560-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24655427</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EMBO Mol Med. 2012 Oct;4(10):1015-28</Citation><ArticleIdList><ArticleId IdType="pubmed">22837174</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2016 Sep;133:165-77</Citation><ArticleIdList><ArticleId IdType="pubmed">27468951</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2017 Jun 27;35(30):3780-3788</Citation><ArticleIdList><ArticleId IdType="pubmed">28579232</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation><ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2018 Aug 16;36(34):5210-5217</Citation><ArticleIdList><ArticleId IdType="pubmed">30017148</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Rev. 2016 Jul;272(1):80-96</Citation><ArticleIdList><ArticleId IdType="pubmed">27319344</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):81-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26678874</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Aug;22(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">27439020</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2010 May;86(2):180-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20153776</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2016 Jun 03;13:87</Citation><ArticleIdList><ArticleId IdType="pubmed">27255185</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2017 Apr;140:55-61</Citation><ArticleIdList><ArticleId IdType="pubmed">28040513</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2013 Sep;23(9):1069-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23938293</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation><ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Crit Rev Biotechnol. 2015 Jun;35(2):235-54</Citation><ArticleIdList><ArticleId IdType="pubmed">24156398</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Mol Immunol. 2010 Sep;7(5):381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20543857</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2016 Dec 16;91(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">27795425</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunology. 2015 Aug;145(4):476-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25762305</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2010 Mar 15;184(6):2756-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20164423</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2017 Jul 3;13(7):1615-1624</Citation><ArticleIdList><ArticleId IdType="pubmed">28277821</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Oct;87(19):10777-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23903833</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2012 Nov 20;3(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Microbiol. 2014 Jan;52(1):67-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24153118</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2012 Oct 04;17(40):20290</Citation><ArticleIdList><ArticleId IdType="pubmed">23078800</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EBioMedicine. 2015 Aug 18;2(10):1438-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26629538</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pathog Glob Health. 2015;109(8):354-62</Citation><ArticleIdList><ArticleId IdType="pubmed">26924345</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 Jul;82(14):6927-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18480438</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2014 Jul 16;32(33):4234-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24120484</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2016 Nov 22;7:13473</Citation><ArticleIdList><ArticleId IdType="pubmed">27874853</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):77-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26678878</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000508 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000508 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:31178378
|texte= Antibody-mediated protection against MERS-CoV in the murine model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:31178378" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |